This study is investigating inflammation in people with Alzheimer's disease. Researchers will measure inflammation markers in your blood and spinal fluid (CSF) and compare them to brain inflammation levels seen on a special scan called a PET scan, using a tracer called 11C-ER176. They also want to see if a treatment called low-dose interleukin-2 (IL-2) immunotherapy, given over 22 weeks, can affect these inflammation markers. You may be eligible if you are 50-86 years old, have a diagnosis of probable Alzheimer's disease, and meet certain blood test requirements. The study aims to understand how inflammation contributes to Alzheimer's and if immunotherapy can help. The current status of this study is unclear.

Study design

This is an interventional study with a planned enrollment of 40 participants. The study is investigating the effects of 11C-ER176 and low-dose interleukin-2 (IL-2) immunotherapy.

What's involved

You would have blood and spinal fluid (CSF) samples taken, and undergo PET scans. These measurements will be taken over a period of 36 months, with immunotherapy given over 22 weeks.

Compensation

Not stated in the trial record.

Follow-up

Your blood and CSF inflammation biomarker levels, as well as brain inflammation measurements, will be assessed at 36 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.